Allergy Therapeutics Plc (AGY) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Animalcare Group Plc

SkinBioTherapeutics Plc

ProBiotix Health Plc

Futura Medical Plc

Allergy Therapeutics Plc

ImmuPharma Plc

Provexis Plc

Cel AI Plc

Gunsynd Plc

Chill Brands Group Plc

Apollon Formularies Plc

Why is Allergy Therapeutics Plc ?

Poor Management Efficiency with a low ROE of 1.26%

The company has been able to generate a Return on Equity (avg) of 1.26% signifying low profitability per unit of shareholders funds

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.18

Poor long term growth as Operating profit has grown by an annual rate -253.65% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.18
The company has been able to generate a Return on Equity (avg) of 1.26% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate -253.65% of over the last 5 years

Negative results in Dec 25

OPERATING CASH FLOW(Y) Lowest at GBP -61.92 MM
PRE-TAX PROFIT(Q) At GBP -15.17 MM has Fallen at -71.74%
NET PROFIT(Q) At GBP -15.76 MM has Fallen at -68.61%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 1.45%, its profits have fallen by -30.2%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Allergy Therapeutics Plc for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Allergy Therapeutics Plc

1.45%

-0.96

61.32%

FTSE 100

17.87%

1.52

11.77%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.87%

EBIT Growth (5y)

-253.65%

EBIT to Interest (avg)

-8.18

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.41

Sales to Capital Employed (avg)

1.78

Tax Ratio

0.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.95%

ROCE (avg)

5.14%

ROE (avg)

1.26%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

111.48

EV to EBIT

-14.06

EV to EBITDA

-16.11

EV to Capital Employed

30.63

EV to Sales

8.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-217.84%

ROE (Latest)

-1013.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at GBP -15.76 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.48 times

NET SALES(Q)

Highest at GBP 36.28 MM

-14What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at GBP -61.92 MM

PRE-TAX PROFIT(Q)

At GBP -15.17 MM has Fallen at -71.74%

NET PROFIT(Q)

At GBP -15.76 MM has Fallen at -68.61%

INTEREST(HY)

At GBP 3.94 MM has Grown at 33.11%

RAW MATERIAL COST(Y)

Grown by 13.07% (YoY

CASH AND EQV(HY)

Lowest at GBP 10.08 MM

DEBT-EQUITY RATIO (HY)

Highest at 392.26 %

Here's what is working for Allergy Therapeutics Plc

Net Sales

Highest at GBP 36.28 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (GBP MM)

Inventory Turnover Ratio

Highest at 2.48 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Allergy Therapeutics Plc

Pre-Tax Profit

At GBP -15.17 MM has Fallen at -71.74%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (GBP MM)

Net Profit

At GBP -15.76 MM has Fallen at -68.61%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (GBP MM)

Operating Cash Flow

Lowest at GBP -61.92 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (GBP MM)

Interest

At GBP 3.94 MM has Grown at 33.11%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (GBP MM)

Cash and Eqv

Lowest at GBP 10.08 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 392.26 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 13.07% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales